07 maj: Alm. Brand A/S - Ugentlig rapportering om aktietilbagekøb
07 maj: Konsolidators udbud overtegnet med 141%
07-05-2019 13:00:00

Zealand Pharma enrolls first patient in Phase 3 extension study of glepaglutide for treatment for short bowel syndrome

Press release – No. 10 / 2019

Zealand Pharma enrolls first patient in Phase 3 extension study of glepaglutide for treatment for short bowel syndrome

  • The Phase 3 extension trial will evaluate long-term safety and efficacy of glepaglutide and enrolls short bowel syndrome (SBS) patients that have completed the pivotal Phase 3 trial.

     

  • The pivotal Phase 3 registration trial with glepaglutide for the treatment of SBS remains on track with results expected in 2020.

     

  • Glepaglutide is a long-acting GLP-2 analog with potential for once-weekly dosing in an auto-injector pen.

Copenhagen, May 7, 2019 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has enrolled the first patient in a Phase 3 extension trial to evaluate the long-term safety and efficacy of glepaglutide treatment in patients with short bowel syndrome (SBS).

Patients who have completed either of the preceding Phase 2 and Phase 3 trials for glepaglutide as treatment for SBS may be eligible to participate in the Phase 3 extension trial. Safety and efficacy will be evaluated throughout a two-year duration.

“We are focused on improving the lives of people living with short bowel syndrome, and this extended trial demonstrates our commitment to delivering better treatment options for SBS,” said Emmanuel Dulac, President and Chief Executive Officer at Zealand Pharma. “We are grateful for the SBS patients that participate in our clinical studies. It’s our intention that this extension trial will help patients continue their pursuit of better health outcomes by improving intestinal absorption with glepaglutide.”

“Transitioning SBS patients into the glepaglutide extension trial is a positive advancement. We interpret it as a sign of good study conduct as well as good tolerability of the product,” added Adam Steensberg, Executive Vice President and Chief Medical and Development Officer at Zealand Pharma.

Additional details about the Phase 3 extension trial of glepaglutide to treat SBS can be found on ClinicalTrials.gov.

For further information, please contact:

Emmanuel Dulac, President and Chief Executive Officer

Tel.: +45 50 60 36 36, e-mail: edu@zealandpharma.com

Lani Pollworth Morvan, Investor Relations and Communication

Tel.: +45 50 60 37 78, e-mail: lpm@zealandpharma.com

About short bowel syndrome (SBS)

SBS is a complex chronic and severe condition associated with reduced or complete loss of intestinal function. Many patients have to be connected to infusion lines and pumps every day, which pose significant restrictions on their ability to engage in daily activities. In addition, they are at risk of experiencing a number of serious and life-threatening complications such as sepsis, blood clots, liver damage and renal impairment.

About glepaglutide

Glepagtluide is a long-acting GLP-2 analog being developed in an auto-injector with potential for convenient weekly administration as treatment for short bowel syndrome (SBS). Zealand Pharma aspires to provide the next generation, best-in-class therapies to help transform the lives of people living with SBS. Glepaglutide has the potential to be a best-in-class GLP-2 therapy, allowing people with SBS a fast, reliable and well-tolerated treatment option to reduce dependence on parenteral support.

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand’s portfolio also includes two clinical license collaborations with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.  

 

Attachment

Z_ID_ORG_FINAL_w_name_rgb_NEW2.jpg

Relateret indhold
03 jun - 
Zealand Pharma/Bryan Garnier: Løfter kursmål til 180 kr..
24 maj - 
Zealand Pharma/SHB: Kursmålet løftes mens anbefalingen ..
22 maj - 
Onsdagens aktier: Overbevisende regnskab sendte Simcorp..
Relateret debat
11:03 - 
Er du lige så overbevist som du var dengang med Soliqua..
10:53 - 
Hvor meget er det Emisphere er steget siden jeg anbefal..
09:26 - 
Weee - 1500 % er løgn og latin. Udelukkende provokation..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
15 jun
ZEAL
Den 30. april 2019 havde Eli Lilly deres Q1 præsentation, hvor de summarisk oplyst at de havde fået ..
10
15 jun
ZEAL
Hej   Semaglutide "startede" også, som injektion, men er blevet formuleret således det nu kan indtag..
7
15 jun
ZEAL
Weew - Hold kæft der er brand i hele butikken. Sælger lortet på mandag ...............................
5
15 jun
ZEAL
Jeg er ikke selv i hverken Zeal eller Novo, så kan i grunden være ligeglad, men må alligevel sige ho..
4
15 jun
ZEAL
Det var flot begrundet - akkurat lige så godt som udkantspolitikerne fra stram kurs :) 
4
07:33
ZEAL
Novo er i gang med Fase 3 forsøg med Sema rettet mod Obesity. Data forventes i midten af 2020. Fase..
3
15 jun
ZEAL
I sin tid er lang tid siden! Semaglutide har bevist at det slår samtlige produkter på alle paremeter..
3
15 jun
ZEAL
Soliqua® 4. kvt. 2018: 27 mill. euro +188.9% Soliqua® 1. kvt. 2019: 22 mill. euro +122.2%   Ja Zeala..
3
11 jun
ZEAL
https://www.euroinvestor.dk/nyheder/2019/06/11/zealand-pharma-presents-dasiglucagon-pivotal-phase-3-..
3
10 jun
ZEAL
Det er godt at se Soliqua er ved at finde sin plads på markedet og jeg håber oprigtigt at Royalty Ph..
3

Lars Christensens Verden - Episode 21: Hvis virksomhedernes betalingsevne svigter, knækker aktiemarkedet

14-06-2019 06:00:00
I episode 21 af podcastserien “Lars Christensens Verden” stilles der skarpt på asset allokering.Euroinvestors chefredaktør Lars Christensen har adm. direktør i og stifter af Copenhagen Allocation Partner (CAP) Morten Kongshaug med i studiet til en samtale om, hvilke værktøjer og indikatorer Morten Kongshaug benytter til at vurdere, om man skal være over- eller undervægt aktier i sin portefølje, og..

Fredagens aktier: Carlsberg sendt til bunds i overvejende rødt C25

14-06-2019 17:02:57
På en dag uden de helt store selskabsnyheder blev Carlsberg fredag sendt til bunds i et rødt C25-indeks, der samlet dykkede 0,7 pct. til 1125,94.Bryggeriaktien faldt 2,9 pct. til 880 kr., hvilket ifølge Martin Munk, senioraktierådgiver i Jyske Bank, kan skyldes, at salgstal fra et analysehus viste svaghed i Vesteuropa - særligt i Storbritannien og Italien.- Der er kommet nye salgstal fra Nielsen (..

Ørsted: Fransk konkurrent vinder havvindudbud i Frankrig

Relaterede nyheder
14-06-2019 12:29:09
Den statsejede franske energikoncern EDF er fredag blevet udråbt til vinderen af en udbudsrunde for havvind i Frankrig.Det oplyser den franske miljøminister, François de Rugy, fredag ifølge nyhedsbureauet Reuters.- EDF er blevet valgt, udtaler han ifølge nyhedsbureauet fredag.Dermed har det franske selskab, der har tyske Innogy og Enbridge som partnere, vundet retten til at opføre en havvindmøllep..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

Zealand Pharma A/S 141,90 0,3% Stigning i aktiekurs
Zealand Pharma Aktiesels.. 141,90 0,3% Stigning i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
16. juni 2019 11:22:20
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190527.1 - EUROWEB6 - 2019-06-16 11:22:20 - 2019-06-16 11:22:20 - 1 - Website: OKAY